Triopsy

Executive Summary

Triopsy is a San Francisco-based digital health company founded in 2020, focused on improving prostate cancer diagnostics through an integrated biopsy system. Its platform aims to enhance the precision, accuracy, and workflow of prostate tissue sampling by delivering longer, more intact tissue cores, which can lead to more confident diagnoses and better patient outcomes. Prostate cancer remains one of the most common malignancies in men, and traditional biopsy methods often suffer from sampling errors and tissue fragmentation, leading to repeat procedures and diagnostic uncertainty. Triopsy's system addresses these pain points by integrating advanced imaging and tissue handling technologies. While the company is still privately held with no publicly disclosed funding or valuation, its technology has the potential to disrupt the urology diagnostics market, which is valued at several billion dollars annually. The company's profile on biopharmguy suggests it is actively seeking visibility, and its location in the Bay Area positions it well to attract talent and partnerships. However, as a private company with limited public information, the risk profile is higher, and near-term traction will depend on regulatory clearances and clinical validation.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Biopsy System60% success
• Q2 2027First Clinical Study Publication Demonstrating Improved Diagnostic Yield50% success
• H1 2027Strategic Partnership or Distribution Agreement with Urology Device Manufacturer40% success